Results

Repare Therapeutics Inc.

05/03/2021 | Press release | Distributed by Public on 05/03/2021 07:25

Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-6306, a First-in-Class, Selective, Oral Inhibitor of PKMYT1